WOBURN, Mass.--(BUSINESS WIRE)--Sirtex Medical Inc., a subsidiary of Sirtex Medical Limited (ASX:SRX), a leading manufacturer of targeted, innovative liver cancer therapies, announced today revenue from sales of SIR-Spheres® microspheres in the U.S. grew 27 percent (32 percent on a constant currency basis) to AUS$57 million (US $59M) for fiscal year 2012. SIR-Spheres microspheres are the only fully FDA-approved microsphere radiation therapy for the treatment of colorectal liver metastases. U.S. dose sales of SIR-Spheres microspheres grew 31 percent for the quarter and 32 percent for the year ending June 30, 2012.
